Radiomics for Diagnosing Liver Diseases and Evaluating Progression
the Department of Medical Ultrasonics, Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, China.
1 other identifier
observational
3,000
1 country
1
Brief Summary
Liver diseases are worldwide problems. liver fibrosis and hepatocellular carcinoma are mostly concerned by clinicians. Radiomcis can improve diagnosis accuracy and evaluate disease progression. Hence,investors try to combine radiomics and ultrasound images together in order to improve diagnosis performances of liver fibrosis, benign and malignant tumor and progression after liver ablations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedFirst Submitted
Initial submission to the registry
July 14, 2017
CompletedFirst Posted
Study publicly available on registry
July 18, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedSeptember 2, 2021
September 1, 2021
12 years
July 14, 2017
September 1, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
liver fibrosis
the degree of liver fibrosis
1 year
benign or malignance
the malignance of liver space occupying lesions
5 years
The incidence of recurrence
the incidence of liver cancer recurrence after ablation
5 years
Study Arms (3)
chronic hepatitis B patients
ultrasound and radiomics
patients with liver space occupying lesions
ultrasound and radiomics
patients undergo ablation
ablation, ultrasound and radiomics
Interventions
Eligibility Criteria
chronic hepatitis B patients /patients with liver space occupying lesions / patients after ablation
You may qualify if:
- HBsAg positive or HBV-DNA detected
- agreed to undergo liver biopsy
- agreed to participated in our study
You may not qualify if:
- combined with other liver disease(eg. HAV/HCV/HDV,alcoholic liver disease)
- combined with HIV
- combined with malignant liver space occupying lesions
- liver transplantation
- pregnant
- the sample size of liver biopsy could not demand: length lower than 15mm, portal areas less than 6.
- For patients classified between benign and malignant tumor
- patients diagnosed with liver space occupying lesions
- with histology results of liver space occupying lesions.
- agreed to participate in our study and signed informed consent.
- ultrasound images cant meet the demand for analysis
- without histology results
- For patients to estimate progression after ablation
- patients diagnosed with hepatocellular carcinoma;
- patients treated with ablation;
- +4 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The department of Ultrasound, the third affiliated hospital of Sun Yat-son University
Guangzhou, Guangdong, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
rongqin zheng, doctor
The department of Ultrasound, the third affiliated hospital of Sun Yat-sen University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 14, 2017
First Posted
July 18, 2017
Study Start
January 1, 2011
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
September 2, 2021
Record last verified: 2021-09